Ionis Pharmaceuticals Inc 2024 Sustainability Report
Company: Ionis Pharmaceuticals Inc
Sector: Manufacturing
Country: United States
Year: 2024
Type: Sustainability Report
Pages: 48
The report describes Ionis' 2024 transition to a fully integrated commercial-stage biotechnology company, including FDA approval and independent launch of TRYNGOLZA. It highlights 1,056 global employees, 1,500+ volunteer hours and $3.5M in corporate contributions. Environmental reporting includes 2,616 metric tons of Scope 1 emissions, 2,530 metric tons of Scope 2 market-based emissions and total Scope 1 and 2 emissions of 5,146. Governance disclosures identify Board oversight of ESG risks and opportunities through the Nominating, Governance and Review Committee.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.